paricalcitol oral solution

Paricalcitol oral solution is a synthetic, biologically active vitamin D analog of calcitriol developed by AbbVie. It is specifically formulated as an oral solution to treat secondary hyperparathyroidism (SHPT) in pediatric patients, particularly those aged 0 to 9 years with stage 5 chronic kidney disease (CKD) undergoing dialysis. Paricalcitol functions as a selective agonist of the vitamin D receptor (VDR). Upon binding to the VDR in the parathyroid glands, it inhibits the synthesis and secretion of parathyroid hormone (PTH), thereby addressing the hormonal imbalances characteristic of SHPT. Unlike non-selective vitamin D compounds, paricalcitol is designed to reduce PTH levels with a lower incidence of hypercalcemia and hyperphosphatemia.

Brand names

Zemplar

Other names

paricalcitol19-nor-1,25-dihydroxyvitamin D2